Methyltriphenoxyphosphonium iodide | 4167-91-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyltriphenoxyphosphonium iodide
• 英文别名: methyltriphenoxyphosphine iodide；Triphenylphosphit-methoiodid；iodo(methyl)triphenoxy-|E5-phosphane；iodo-methyl-triphenoxy-λ5-phosphane
• CAS: 4167-91-3
• 化学式: C₁₉H₁₈IO₃P
• 分子量: 452.228
• InChiKey: BPTHCFBWOUNCBG-UHFFFAOYSA-N

物化性质

• 熔点：
  145-147 °C

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090

反应信息

• 作为反应物：
  描述：

  12-(2-bromoprop-2-enoxy)dodecan-1-ol 、 Methyltriphenoxyphosphonium iodide 以80%的产率得到
  参考文献：
  名称：

  GENET J. P.; KAHN P., TETRAHEDRON LETT., 1980, 21, NO 16, 1521-1524

  摘要：

  DOI：
• 作为试剂：
  描述：

  勒胖停 在 Methyltriphenoxyphosphonium iodide 、 ammonium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 rhaponticin
  参考文献：
  名称：

  Regioselective synthesis and initial evaluation of a folate receptor targeted rhaponticin prodrug

  摘要：

  To improve the therapeutic effect of rhaponticin (RHA), a folate receptor (FR) targeted RHA prodrug was designed and regioselectively synthesized by utilizing a hydrophilic peptide spacer linked to folic acid (FA) via a releasable disulfide linker. A series of biological evaluation was investigated in vitro and in vivo. The positive results of biological investigations warrant further preclinical study before this novel targeted chemotherapeutic is considered for clinical investigation. (C) 2012 Jun Fan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  DOI：

  10.1016/j.cclet.2012.08.006

文献信息

• MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B
  申请人：FANG Francis G.

  公开号：US20160264594A1

  公开（公告）日：2016-09-15

  The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

  本发明提供了通过大环化策略合成厄利布林或其药学上可接受的盐（例如，甲磺酸厄利布林）的方法。本发明的大环化策略涉及将非大环中间体经过碳-碳键形成反应（例如，烯化反应（例如，霍默-沃兹沃斯-埃蒙斯烯化反应），迪克曼反应，催化环内烯烃交换反应，或野崎-桥山-岸反应）处理，以得到大环中间体。本发明还提供了在合成厄利布林或其药学上可接受的盐方面有用的中间体化合物及其制备方法。
• Carbidopa and L-Dopa Prodrugs and Methods of Use
  申请人：AbbVie Inc.

  公开号：US20160106765A1

  公开（公告）日：2016-04-21

  The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

  本公开涉及（a）卡比多巴前药，（b）包括卡比多巴前药和/或L-多巴前药的药物组合和组成物，以及（c）治疗帕金森病和相关疾病的方法，包括向患有帕金森病的受试者施用卡比多巴前药和L-多巴前药。
• A liquid crystal compound having (a) deuterium atom (s) and a liquid crystal composition comprising the said compound
  申请人：CHISSO CORPORATION

  公开号：EP0735015A3

  公开（公告）日：1997-06-11

  Object It is possible to control a pitch without any increase of a viscosity and any decrease of a voltage holding ratio etc. in various liquid crystal compositions.Structure Provision of a liquid crystal compound with (an) optically active carbon atom(s) bonded to (a) deuterium atom(s) and a liquid crystal compound having characteristics suitable for various liquid crystal display methods at the same time.Effect It is possible to prepare a liquid crystal composition without use of a chiral dopant. It is possible to control a pitch length and a spiral direction by selection of a stereochemistry in the compound and (a) position(s) of the deuterium atom(s).

  目标：在各种液晶组成中，可以控制电压保持比率等参数而不增加粘度。 结构：提供一种液晶化合物，其中光学活性碳原子与氘原子结合，并具有适用于各种液晶显示方法的特性。 效果：可以制备一种不使用手性掺杂剂的液晶组分。可以通过化合物的立体化学和氘原子的位置选择来控制螺旋方向和螺旋周期长度。
• Synthesis of L-3,4-Didehydroproline: Favoured Orientation in the Key-Step Elimination Reaction
  作者：J. -R. Dormoy

  DOI：10.1055/s-1982-29931

  日期：——
• The Constitution and Stereochemistry of Artemisin^1,2
  作者：Masao Sumi

  DOI：10.1021/ja01551a027

  日期：1958.9